DEFA14A filed Apr 24, 2026 at 16:04 ET
Regeneron Pharmaceuticals has filed definitive additional proxy soliciting materials (DEFA14A) with the SEC. This is a routine filing related to an upcoming shareholder vote, likely covering items such as director elections, executive compensation, or other corporate governance matters. The filing is from the registrant and is definitive, indicating that the final details for the vote have been provided to shareholders. There is no indication of activist involvement or contentious issues.